Health
Perfect Diary's Parent Company Yatsen Group Officially Unveils Global Innovation and R&D Center
Initial Investment of Over RMB 80 Million Marks a New Era of Innovation for the Company SHANGHAI, June 5, 2024 /PRNewswire/ -- On May 28, Yatsen Group, the parent company of Perfect Diary, held the grand opening of the new Global Innovation R&D Center ("the Center") inShanghai. As the first¹ glo...
GC Genome Highlights Promising New Approach for Non-invasive Colorectal Cancer Detection at ASCO 2024
YONGIN, South Korea, June 5, 2024 /PRNewswire/ -- GC Genome Corporation, a leading diagnostics company, presented new data from its AI-based liquid biopsy platform for non-invasive colorectal cancer (CRC) detection at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Conducted...
Live from ASCO 2024 | Oral Report Released Latest Data of Olverembatinib in SDH-Deficient GIST, Including a CBR of 92.3%
SUZHOU, China and ROCKVILLE, Md., June 4, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated clinical data of olvere...
Live from ASCO 2024 | Ascentage Pharma Releases Updated Data Showing Promising Efficacy and Safety of Lisaftoclax in Patients with WM
SUZHOU, China, and ROCKVILLE, Md., June 4, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated results from a global,...
CARsgen Presents Updated Results on Satri-cel in Nature Medicine and at 2024 ASCO
SHANGHAI, June 4, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the final follow-up results of the investigator-initiated trial C...
FDA Clearance For Gastrointestinal Parasite Detection Kit
MELBOURNE, Australia, June 4, 2024 /PRNewswire/ -- Genetic Signatures Limited [ASX:GSS]("GSS" or the "Company"), a global molecular diagnostics company announces that the US Food & Drug Administration ("FDA") has cleared the Company'sEasyScreen™ Gastrointestinal Parasite Detection Kit and GS1 aut...
MicroAlgo Inc. (NASDAQ: MLGO) Announced to Jointly Establish a Micro-Consciousness Quantum Research Center With WIMI (NASDAQ: WIMI)
BEIJING, June 4, 2024 /PRNewswire/ -- MicroAlgo Inc. (NASDAQ: MLGO) (the "Company" or "MicroAlgo"), today announced that MicroAlgo and WiMi will jointly establish a micro-consciousness quantum research center. It will integrate physics, mathematics, medicine, genetics, computer science, biology, ...
Qingsong Health Corporation Elevates Healthcare and Inclusive Development with AI Advancements at WSIS+20 Forum
BEIJING, June 4, 2024 /PRNewswire/ -- At The World Summit on the Information Society (WSIS) Forum inGeneva, the Qingsong Health Corporation from China, known for its technology-driven healthcare solutions, showcased the latest AI advancements for improved and inclusive healthcare. The WSIS+20 For...
GCBP Sponsors 2024 Spring Symposium for KASBP and Present Research Findings
YONGIN, South Korea, June 4, 2024 /PRNewswire/ -- GC Biopharma announced that it will attend 2024 Spring Symposium of the Korean American Society in Biotech and Pharmaceuticals (KASBP) onJune 7-8th at Waltham, Massachusetts as a sponsor to share keynote presentation, present Korean Scientist Awar...
Live from ASCO 2024 | Updated Data of Bcl-2 Inhibitor Lisaftoclax Combined with Azacitidine in Patients with AML Demonstrate Promising Efficacy and Manageable Safety
SUZHOU, China and ROCKVILLE, Md., June 4, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released the latest results from a Phase...
Fapon Biopharma Announces a Safer Immunotherapy for Cancers
SAN DIEGO, June 3, 2024 /PRNewswire/ -- At Bio International Convention 2024, which is taking place here inSan Diego during June 3-6, Fapon Biopharma, an innovator in developing therapeutic antibodies and fusion proteins, has announced an immunocytokine with modified IL-10M fused to anti-PD-1 ant...
Datasea Agreement already provided $2.8 million Information Service for its Highly Specialized 5G-AI Communications Platform
Agreement to Have Powerful Revenue Impact and is Expected to Lead to More Lucrative Contracts BEIJING, June 3, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada company engaged in innovative business segments in high-tech intelligent acoustics and 5G-Artifici...
Minghui Pharmaceutical Presents Phase 1/2 Clinical Data of MHB088C (B7-H3 ADC) as Monotherapy for the Treatment of Patients with Recurrent or Metastatic Solid Tumors at the 2024 ASCO Annual Meeting
SHANGHAI, June 3, 2024 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a late-stage clinical biopharmaceutical company, announced today that the preliminary Phase 1/2 clinical data of MHB088C (B7-H3 ADC) was presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in an ora...
Visionary Pioneering Innovation Across Four Key Frontiers
TORONTO, June 3, 2024 /PRNewswire/ -- Visionary Holdings Inc. (the "Company") (NASDAQ: GV), a private education provider with technology of artificial intelligence and life science on the cutting edge, with subsidiaries inCanada and market partners inChina, today announced the Company is pioneeri...
Psylo Announces First Close on $8 Million Series Seed Financing to Advance Next-Generation Neuroplastogens at BIO Conference in San Diego
Innovative biotech company pioneers PSYLO-100X, a non-hallucinogenic neuroplastogen with promising therapeutic potential SAN DIEGO, June 3, 2024 /PRNewswire/ -- Psylo, a leading biotechnology company focused on the development of next-generation neuroplastogens, today announced at the BIO Confer...
Formosa Laboratories Completes the Acquisition of Synchem to Expand North American CDMO Footprint
TAOYUAN, June 3, 2024 /PRNewswire/ -- Formosa Laboratories, Inc., a leading API supplier and CDMO headquartered inTaiwan, has successfully completed its acquisition of SynChem, Inc., a contract research laboratory located in suburban Chicago. SynChem will now operate under the new name SynChem-For...
MGI Tech's DNBSEQ-E25 and G99 Platforms Set Record for Sequencing Applications on Mount Everest
SHENZHEN, China, June 2, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, recently set a new record for sequencing applications by successfully running sample testing on its cutting-edge DNBSEQ-E25 ...
Leads Biolabs' Innovative Cancer Treatment LBL-024, an Anti-PDL1/4-1BB Bispecific Antibody Achieved Outstanding Phase II Results, Has Been Presented in Clinical Science Symposium at 2024 ASCO Annual Meeting.
NANJING, China, June 2, 2024 /PRNewswire/ -- The annual meeting of the American Society of Clinical Oncology (ASCO) commenced onMay 31st, Showcasing groundbreaking cancer research from around the world. According to official information, over 7,000 abstracts were submitted this year. After rigoro...
China Medical University Hospital (CMUH, Taiwan) Signs MOU with Malaysian International Medical University
Wistron and imedtac jointly promote leading medical products with CMUH in Malaysia TAICHUNG, Taiwan, June 2, 2024 /PRNewswire/ -- China Medical University Hospital (CMUH,Taiwan) and the Malaysian International Medical University (IMU), the first and top private medical and health science un...
Keymed Biosciences Announces Long-term Efficacy and Safety Data from a Phase III Clinical Trial of Stapokibart for the Treatment of Moderate-to-severe Atopic Dermatitis
CHENGDU, China, June 2, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced the long-term efficacy and safety data of a Phase III clinical trial of stapokibart injection in patients with moderate-to-severe atopic dermatitis (AD) has been released by way of oral presentation...
Week's Top Stories
Most Reposted
Thailand Tops 2024 Consumer Review Awards by Agoda
[Picked up by 329 media titles]
2024-09-26 11:00WARHAMMER 40,000: SPACE MARINE VR - DEFENDERS OF AVARAX NOW AVAILABLE AT ZERO LATENCY VR VENUES WORLDWIDE
[Picked up by 314 media titles]
2024-09-26 00:00Advantech Unveils Expanded Singapore Office to Boost ASEAN Presence and Support AIoT Innovations with Strategic Partnerships
[Picked up by 312 media titles]
2024-09-23 13:37Circles Partners with Telkomsel, Providing an Advanced Software-as-a-Service (SaaS) Platform to Enhance Customer Digital Experience
[Picked up by 297 media titles]
2024-09-27 10:00RuggON Debuts at the Largest Mining Expo, MINExpo 2024 Showcasing Rugged Solutions for the Trillion-Dollar Mining Market
[Picked up by 294 media titles]
2024-09-23 22:00